The Relationship of Carotid Intima-Media Thickness with Cell Adhesion Molecules and Pentraxin-3 in Patients with Psoriatic Arthritis

Abstract

Aim Cardiovascular morbidity is increased in patients with psoriatic arthritis (PsA) compared to the general population. Several recent studies have indicated that pentraxin 3 (PTX-3) and cell adhesion molecules (CAMs) might be independent biomarkers of subclinical atherosclerosis. In this study, we aimed to determine the relationship of CAMs and PTX-3 with carotid intima media thickness (CIMT) in patients with PsA and to compare CIMT and serum levels of these biomarkers in patients with healthy controls (HCs).

Method PsA patients fulfilling the CASPAR (Classification criteria for Psoriatic Arthritis) criteria without traditional cardiovascular (CV) comorbidity and HCs without autoimmune and/or CV disease were included in this cross-sectional study. Carotid artery Doppler ultrasound examinations were conducted by a single radiologist blinded to the participants’ clinical characteristics. Serum vascular adhesion molecule 1 (VCAM-1), intercellular adhesion molecule 1 (ICAM-1), E-selectin, and PTX-3 concentrations were analized.

Results 43 PsA patients (27 females, mean age 42.49±11.70 years, and a mean disease duration of 9.37±7.96 years) and 37 HCs (28 females, mean age 42.16±11.38 years) were included. In regression analyses, age and PTX-3 were found to be the best predictors of CIMT in patients with PsA. CIMT was significantly higher in PsA patients compared with HCs (0.63±0.18 vs. 0.49±0.10 mm, p<0.01). In te PsA group, serum levels of PTX-3, ICAM-1, and VCAM-1 were also significantly higher than HCs. CIMT correlated positively with age, disease duration, PTX-3, ICAM-1, and VCAM-1 (p<0.05).

Conclusion In our study, age and serum level of PTX-3 were found to be the predictors of CIMT in patients with PsA without CV comorbidity. This outcome highlights the importance of monitoring CIMT and serum level of PTX-3 as CV risk factors in PsA patients.

Keywords

psoriatic arthritis - aterosclerosis - carotid intima–media thickness - cell adhesion molecules - pentraxin 3

Schlüsselwörter

psoriasis-arthritis - arteriosklerose - karotis-intima-media-dicke - zelladhäsionsmoleküle - pentraxin 3published online 2022

Publikationsverlauf

Artikel online veröffentlicht:
27. Oktober 2022

• References

• 1 Tobin A-M, Veale DJ, Fitzgerald O. et al. Cardiovascular disease and risk factors in patients with psoriasis and psoriatic arthritis. The Journal of rheumatology 2010; 37: 1386-1394
• 2 Mok C, Kwok C, Ho L. et al. Life expectancy, standardized mortality ratios, and causes of death in six rheumatic diseases in Hong Kong, China. Arthritis & Rheumatism 2011; 63: 1182-1189
• 3 Di Minno MND, Ambrosino P, Lupoli R. et al. Cardiovascular risk markers in patients with psoriatic arthritis: a meta-analysis of literature studies. Annals of medicine 2015; 47: 346-353
• 4 Kolliker Frers RA, Cosentino V, Tau J. et al. Immune-mediated inflammation promotes subclinical atherosclerosis in recent-onset psoriatic arthritis patients without conventional cardiovascular risk factors. Frontiers in immunology 2018; 9: 139
• 5 Terekeci MH, Şahan B, Top C. Hücre adezyon molekülleri. EVALUATION 2008; 33: 38
• 6 Darka Ö. Hücre Adezyon Molekülleri veEnflamasyondaki Rolleri. Türkiye Klinikleri Mikrobiyoloji Enfeksiyon Dergisi 2003; 2: 36-43
• 7 Ridker P. Novel risk factors and markers for coronary disease. Advances in internal medicine 2000; 45: 391
• 8 Ristagno G, Fumagalli F, Bottazzi B. et al. Pentraxin 3 in cardiovascular disease. Frontiers in immunology 2019; 10: 823
• 9 Norata GD, Marchesi P, Pulakazhi Venu VK. et al. Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis. Circulation 2009; 120: 699-708
• 10 Jenny NS, Arnold AM, Kuller LH. et al. Associations of pentraxin 3 with cardiovascular disease and all-cause death: the Cardiovascular Health Study. Arteriosclerosis, thrombosis, and vascular biology 2009; 29: 594-599
• 11 Deban L, Russo RC, Sironi M. et al. Regulation of leukocyte recruitment by the long pentraxin PTX3. Nature immunology 2010; 11: 328-334
• 12 Balta S. Endothelial dysfunction and inflammatory markers of vascular disease. Current Vascular Pharmacology 2021; 19: 243-249
• 13 Tas SW, Maracle CX, Balogh E. et al. Targeting of proangiogenic signalling pathways in chronic inflammation. Nature Reviews Rheumatology 2016; 12: 111-122
• 14 Fromm S, Cunningham C, Dunne M. et al. Enhanced angiogenic function in response to fibroblasts from psoriatic arthritis synovium compared to rheumatoid arthritis. Arthritis research & therapy 2019; 21: 1-11
• 15 Taylor W, Gladman D, Helliwell P. et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology 2006; 54: 2665-2673
• 16 Wells G, Becker J, Teng J. et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Annals of the rheumatic diseases 2009; 68: 954-960
• 17 Garrett S, Jenkinson T, Kennedy LG. et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. The Journal of rheumatology 1994; 21: 2286-2291
• 18 Fries JF, Spitz P, Kraines RG. et al. Measurement of patient outcome in arthritis. Arthritis & Rheumatism 1980; 23: 137-145
• 19 Calin A, Garrett S, Whitelock H. et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. The Journal of rheumatology 1994; 21: 2281-2285
• 20 Jenkinson TR, Mallorie P, Whitelock H. et al. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. The Journal of Rheumatology 1994; 21: 1694-1698
• 21 Fredriksson T, Pettersson U. Severe psoriasis–oral therapy with a new retinoid. Dermatology 1978; 157: 238-244
• 22 Schoels M. Psoriatic arthritis indices. Clin Exp Rheumatol 2014; 32: S109-S112
• 23 Mumtaz A, Gallagher P, Kirby B. et al. Development of a preliminary composite disease activity index in psoriatic arthritis. Annals of the rheumatic diseases 2011; 70: 272-277
• 24 Doward L, Spoorenberg A, Cook S. et al. Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Annals of the rheumatic diseases 2003; 62: 20-26
• 25 Finlay AY, Khan G. Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clinical and experimental dermatology 1994; 19: 210-216
• 26 Tam LS, Shang Q, Li EK. et al. Subclinical carotid atherosclerosis in patients with psoriatic arthritis. Arthritis Care & Research: Official Journal of the American College of Rheumatology. 2008; 59: 1322-1331
• 27 Corrales A, Parra JA, González-Juanatey C. et al. Cardiovascular risk stratification in rheumatic diseases: carotid ultrasound is more sensitive than Coronary Artery Calcification Score to detect subclinical atherosclerosis in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 2013; 72: 1764-1770
• 28 Kawada T, Andou T, Fukumitsu M. Metabolic syndrome showed significant relationship with carotid atherosclerosis. Heart and vessels 2016; 31: 664-670
• 29 Atzeni F, Sarzi-Puttini P, Sitia S. et al. Coronary flow reserve and asymmetric dimethylarginine levels: new measurements for identifying subclinical atherosclerosis in patients with psoriatic arthritis. The Journal of rheumatology 2011; 38: 1661-1664
• 30 Magro-Checa C, Orgaz-Molina J, Rosales-Alexander J. et al. SAT0295 Comparison of subclinical carotid atherosclerosis in patients with psoriatic arthritis, psoriasis alone and controls. Annals of the Rheumatic Diseases 2013; 71: 572
• 31 Garg N, Krishan P, Syngle A. Atherosclerosis in psoriatic arthritis: a multiparametric analysis using imaging technique and laboratory markers of inflammation and vascular function. The International journal of angiology: official publication of the International College of Angiology, Inc 2016; 25: 222
• 32 Shen J, Lam SH, Shang Q. et al. Underestimation of risk of carotid subclinical atherosclerosis by cardiovascular risk scores in patients with psoriatic arthritis. The Journal of rheumatology 2018; 45: 218-226
• 33 Santos JCD, Cruz MS, Bortolin RH. et al. Relationship between circulating VCAM-1, ICAM-1, E-selectin and MMP9 and the extent of coronary lesions. Clinics 2018; 73
• 34 Dessein PH, Joffe BI, Singh S. Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis. Arthritis research & therapy 2005; 7: 1-10
• 35 Okan G, Baki AM, Yorulmaz E. et al. Serum Visfatin, Fetuin-A, and Pentraxin 3 Levels in Patients With Psoriasis and Their Relation to Disease Severity. Journal of clinical laboratory analysis 2016; 30: 284-289
• 36 Uysal S, Yilmaz F, Karatoprak K. et al. The levels of serum pentraxin3, CRP, fetuin-A, and insulin in patients with psoriasis. Eur Rev Med Pharmacol Sci 2014; 18: 3453-3458
• 37 Sunar I, Ozdemirel A, Sürmeli Z. et al. AB0762 The relationship between serum pentraxin-3 levels, cardiovascular disease risk and disease activity in psoriatic arthritis patients. BMJ Publishing Group Ltd; 2017
• 38 Ješe R, Rotar Ž, Tomšič M. et al. The cut-off values for the intima–media complex thickness assessed by colour Doppler sonography in seven cranial and aortic arch arteries. Rheumatology 2021; 60: 1346-1352
• 39 Sammel AM, Xue M, Karsten E. et al. Limited utility of novel serological biomarkers in patients newly suspected of having giant cell arteritis. International Journal of Rheumatic Diseases 2021; 24: 781-788
• 40 Venhoff N, Schmidt WA, Lamprecht P. et al. Efficacy and safety of secukinumab in patients with giant cell arteritis: study protocol for a randomized, parallel group, double-blind, placebo-controlled phase II trial. Trials 2021; 22: 543
• 41 Baraliakos X, Gossec L, Pournara E. et al. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. Annals of the rheumatic diseases 2021; 80: 582-590